107867-51-6

Basic information

• Product Name: 2,3-Diamino-5-trifluoromethylpyridine
• Synonyms: 2,3-Diamino-5-trifluoromethylpyridine;5-(TrifluoroMethyl)pyridine-2,3-diaMine;2,3-PyridinediaMine,5-(trifluoroMethyl)-
• CAS NO: 107867-51-6
• Molecular Formula: C₆H₆F₃N₃
• Molecular Weight: 177.13
• Product Categories: Pyridine series
• Mol File: 107867-51-6.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 296.682 °C at 760 mmHg
• Flash Point: 133.229 °C
• Appearance: /
• Density: 1.467 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.539
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 4.43±0.49(Predicted)
• CAS DataBase Reference: 2,3-Diamino-5-trifluoromethylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Diamino-5-trifluoromethylpyridine(107867-51-6)
• EPA Substance Registry System: 2,3-Diamino-5-trifluoromethylpyridine(107867-51-6)

Safety Data

• Hazardous Substances Data: 107867-51-6(Hazardous Substances Data)

Usage

General Description

2,3-Diamino-5-trifluoromethylpyridine, also known as DA-5TFMP, is a chemical compound with the molecular formula C6H5F3N4. It is a pyridine derivative with two amino groups and a trifluoromethyl group attached to the pyridine ring. 2,3-Diamino-5-trifluoromethylpyridine is used in the pharmaceutical industry as an intermediate in the synthesis of various drugs, particularly in the development of anticancer and antiviral medications. It has also been studied for its potential use in the treatment of neurological disorders. Its unique chemical structure and properties make it a valuable building block for the development of novel pharmaceutical compounds. However, it is important to handle this compound with care and caution, as it can be hazardous if not used properly.

InChI:InChI=1/C6H6F3N3/c7-6(8,9)3-1-4(10)5(11)12-2-3/h1-2H,10H2,(H2,11,12)

Upstream product

• 79456-30-7 3-bromo-5-trifluoromethyl-pyridin-2-ylamine 
• 438191-02-7 1'-(7-chloro-1H-benzimidazol-2-yl)-spiro[isobenzofuran-1,4'-piperidin]-3-one 
• 53359-69-6 5-(Trifluoromethyl)-3-nitro-2-aminopyridine 
• 74784-70-6 2-amino-5-trifluoromethylpyridine 

Downstream Products

• 122771-62-4 2-amino-3-(2-methyl-6-methoxycarbonylaminobenzylamino)pyridine 
• 1201597-38-7 2-(chloromethyl)-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridine 
• 168123-87-3 7-trifluoromethyl-1,4-dihydropyrido[2,3-b]pyrazine-2,3-dione 

Relevant articles and documents

Mild and efficient addition of carbon nucleophiles to condensed pyridines: influence of structure and limits of applicability

[Figure not available: see fulltext.] A number of azolo- and azinopyridines with varying substituents and annulated heterocycles were synthesized and examined in dearomatization reactions with carbon nucleophiles. Depending on the structure, the resulting covalent σ-adducts were formed either under basefree conditions or in Et3N-promoted process to give functionalized condensed dihydropyridines. Quantum-chemical calculations of the global electrophilicity index derived from FMO energies of azolopyridine series were performed to explain reactivity toward neutral and anionic C-nucleophiles. These values may be useful for qualitative prediction of particular reactivity pattern.

NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES

The present invention relates to novel heterocyclic compounds useful in preparing drugs for treatment of diseases associated with various functions of the histamine 4 receptor. Especially, the said drugs are useful for treatment of inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itch, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritic pain, autoimmune thyroid disease, immune-mediated (also known as type I) diabetes, lupus, post-operative adhesions, vestibular disorders and cancer.

Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H- benzimidazoles

The vanilloid receptor-1 (VR1 or TRPV1) is a membrane-bound, nonselective cation channel that is predominantly expressed by peripheral neurons sensing painful stimuli. TRPV1 antagonists produce antihyperalgesic effects in animal models of inflammatory and neuropathic pain. Herein, we describe the synthesis and the structure-activity relationships of a series of 2-(4-pyridin-2- ylpiperazin-1-yl)-1H-benzo-[d]imidazoles as novel TRPV1 antagonists. Compound 46ad was among the most potent analogues in this series. This compound was orally bioavailable in rats and was efficacious in blocking capsaicin-induced flinch in rats in a dose-dependent manner. Compound 46ad also reversed thermal hyperalgesia in a model of inflammatory pain, which was induced by complete Freund's adjuvant (CFA).